Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Do ASX biotech shares offer 'good buying' after the sell-off? Experts weigh in
Share Market News
Avecho (ASX:AVE) share price rockets 83% on milestone announcement
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sale, and licensing of products incorporating its patented platform technology TPM, for the pharmaceutical, skincare and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.
|30 Nov 2023||$0.00||$0.00||0.00%||120,000||$0.00||$0.00||$0.00|
|29 Nov 2023||$0.00||$0.00||0.00%||1,017,253||$0.00||$0.00||$0.00|
|24 Nov 2023||$0.00||$0.00||0.00%||27,619||$0.00||$0.00||$0.00|
|23 Nov 2023||$0.00||$0.00||0.00%||1,855,445||$0.00||$0.00||$0.00|
|22 Nov 2023||$0.00||$0.00||0.00%||1,200,086||$0.00||$0.00||$0.00|
|21 Nov 2023||$0.00||$0.00||0.00%||316,344||$0.00||$0.00||$0.00|
|20 Nov 2023||$0.00||$0.00||0.00%||1,730,181||$0.00||$0.00||$0.00|
|17 Nov 2023||$0.00||$0.00||0.00%||1,454,721||$0.00||$0.01||$0.00|
|16 Nov 2023||$0.00||$0.00||0.00%||4,422,037||$0.00||$0.00||$0.00|
|15 Nov 2023||$0.00||$0.00||0.00%||2,625,924||$0.00||$0.01||$0.00|
|14 Nov 2023||$0.01||$0.00||0.00%||11,638,553||$0.00||$0.01||$0.00|
|13 Nov 2023||$0.00||$0.00||0.00%||1,950,351||$0.00||$0.00||$0.00|
|10 Nov 2023||$0.00||$0.00||0.00%||500,000||$0.00||$0.00||$0.00|
|09 Nov 2023||$0.00||$0.00||0.00%||1,447,678||$0.00||$0.00||$0.00|
|07 Nov 2023||$0.00||$0.00||0.00%||126,362||$0.00||$0.00||$0.00|
|06 Nov 2023||$0.00||$0.00||0.00%||1,092,398||$0.00||$0.00||$0.00|
|22 Nov 2023||Gregory (Greg) Collier||Issued||5,833,333||$34,999||
Issue of securities.
|22 Nov 2023||Gregory (Greg) Collier||Issued||8,749,999||$34,999||
Issue of securities.
|22 Nov 2023||Matthew McNamara||Issued||2,499,999||$9,999||
Issue of securities.
|22 Nov 2023||Matthew McNamara||Issued||1,666,666||$9,999||
Issue of securities.
|10 May 2023||Gregory (Greg) Collier||Issued||2,000,000||$12,000||
|10 May 2023||Ross Murdoch||Issued||2,499,999||$9,999||
|10 May 2023||Ross Murdoch||Issued||1,666,666||$9,999||
|Dr Gregory (Greg) Collier||Non-Executive ChairmanNon-Executive Director||Apr 2019||
Dr Collier has more than 20 years of experience spanning operational, clinical and scientific aspects of pharmaceutical research, development and commercialisation. Dr Collier has led the planning and execution of multiple commercial transactions including in and out-licensing deals and major M&A activities, and he has successfully taken a drug from discovery through to regulatory approval. Notably, Dr Collier steered ChemGenex Pharmaceuticals Limited from a research-based Company with a market capitalisation of $10 million to a Company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011, ChemGenex was sold to Cephalon Inc. (now a subsidiary of Teva Pharmaceuticals Industries Limited) for $230 million. Prior to his commercial pharmaceutical career, Dr Collier had an outstanding academic career resulting in over 150 peer-reviewed publications and senior authorship on 33 patents. Dr Collier was the inaugural Alfred Deakin Professor at Deakin University, and also held positions at Melbourne University, Monash University and the University of Toronto. In 2010, Dr Collier was awarded the Roche Award of Excellence for his contribution to the biotechnology industry.
|Dr Ross Murdoch||Non-Executive Director||Apr 2015||
Dr Murdoch joined Avecho as CEO in January 2015 and was appointed director in April 2015. He has almost 30 years of experience as a leader within the global healthcare, pharmaceutical and biotechnology industries. He has held senior management and executive positions in Australia, the USA and Europe, responsible for the strategy, development and commercialisation of products, and product portfolios and for building and rebuilding new and existing businesses. Highlights of his career include being Senior Vice President at Shire Pharmaceuticals, based in the USA and Switzerland. He founded and grew both the Emerging Products Business and Haematology Business and the President and COO of Prana Biotechnology Limited based in Australia. Dr Murdoch has a BSc degree with Honours from Monash University, a PhD in Clinical Pharmacology from the University of Melbourne and additional postgraduate training in Health Economics from Monash University Business School. He is also a Graduate of the Australian Institute of Company Directors.
|Mr Matthew Patrick McNamara||Non-Executive Director||Jan 2020||
Mr McNamara has over 30 years executive and funds management experience in the healthcare and medical sciences sector. He has a BSc (Hons) in Molecular Biology, has an MBA, and is a GAICD. In 2003, he founded BioBridge Australia, a biotechnology commercialisation advisory company and advised a number of public biotechnology / investment companies. Mr McNamara is currently Director and Chief Investment Officer of Horizon 3 Healthcare, a healthcare fund manager that has invested in Avecho Biotechnology Limited through trustee Melbourne Securities Corporation Limited. He is presently a director of Microbio Pty Ltd, ESN Cleer Pty Ltd, Cardiac Dimensions Pty Ltd, and Grey Innovation Investment Partners Pty Ltd. He has held previous directorship in Adherium Ltd (ASX: ADR), Avita Medical Ltd (ASX: AVH), Bioxyne Ltd (ASX: BXN) and Saluda Medical Pty Ltd. Mr McNamara has also served as CIO of BioScience Manager Pty Ltd, and was CEO of SciCapital Pty Ltd, a Life Sciences Venture Capital fund.
|Ms Melanie Jaye Leydin||Chief Financial OfficerCompany Secretary||Dec 2018||
|Dr Paul Gavin||Chief Executive Officer||May 2020||
|Paul Gavin||Chief Executive Officer||
|Melanie Jaye Leydin||Chief Financial OfficerCompany Secretary||
|Mr Mark Gregory Kerr & Mrs Linda Marie Kerr <Lindmark Inv Staff S/F A/C>||181,979,391||9.90%|
|HSBC Custody Nominees (Australia) Limited||104,651,014||5.69%|
|Rosscope Pty Ltd <Ross Copeland Family A/C>||85,513,129||4.65%|
|Mr Mark Gregory Kerr <Lindmark Inv Staff S/F A/C>||67,153,797||3.65%|
|Melbourne Securities Corporation Limited <Horizon 3 Biotech Fund A/C>||59,345,624||3.23%|
|BNP Paribas Noms Pty Ltd <DRP>||39,500,198||2.15%|
|Servbond Pty Limited <Servbond Pty Ltd S/F A/C>||25,000,000||1.36%|
|Citicorp Nominees Pty Limited||22,817,772||1.24%|
|FF Okram Pty Ltd <FF Okram A/C>||20,494,147||1.12%|
|Kazakco Pty Ltd <Kent Family A/C>||20,000,000||1.09%|
|Mr Tony Domenic Amato||19,500,712||1.06%|
|Churchcourt Pty Limited||18,462,500||1.00%|
|Mr Ross Graham Copeland & Mrs Gina Susan Copeland <Publicity Press Super A/C>||16,912,918||0.92%|
|Mr Yong Wang||16,515,349||0.90%|
|Mrs Susan Margaret Chudleigh & Mr John West Chudleigh||16,000,000||0.87%|
|Dr Maurice Arthur Trewhella & Mrs Elizabeth Trewhella <Simpetejen Super Fund A/C>||16,000,000||0.87%|
|BHL Pension Pty Ltd <BHL Pension Fund A/C>||15,000,000||0.82%|
|Mr Gary Dean Shaw||15,000,000||0.82%|
|Mr Brandon Armon Batagol||13,932,870||0.76%|
|10 Bolivianos Pty Ltd||13,313,391||0.72%|